Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)
NCT02538042 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87
Last updated 2018-11-14
Summary
The central objective of the project is to evaluate the effect of incorporating smoking related contexts into very low nicotine content (VLNC) cigarette extinction trials on clinically relevant, smoking-related outcomes. Adult smokers interested in quitting smoking (N=80) will be interviewed and trained to take pictures where they smoke cigarettes. Following taking these pictures, participants will then be switched to smoke VLNCs while wearing a 21 mg/d nicotine patch (EXT) for three weeks. During this 3-week treatment period, half of the sample (n=40) will be randomly assigned to undergo six, 60-minute sessions of multiple context extinction (MCE+) during which they will view smoking-related environments and smoke their assigned cigarettes. The remaining 40 participants will undergo control MCE (exposure to nature environments; MCE-) and smoke their assigned cigarettes. At the end of the three weeks, participants will quit smoking and continue to wear the nicotine patch while being followed during a 10-week abstinence period. Participants will also complete a follow-up phone call 6 months after their quit day.
Conditions
- Cigarette Smoking
Interventions
- DRUG
-
Nicotine Patch
Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
- DRUG
-
SPECTRUM Nicotine Research Cigarettes (0.07 mg)
For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
- BEHAVIORAL
-
MCE+
During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
- BEHAVIORAL
-
MCE-
During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
National Institute on Drug Abuse (NIDA)
collaborator NIH -
Francis McClernon, Ph.D.
lead OTHER
Principal Investigators
-
Francis J McClernon, Ph.D · Duke University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-10-08
- Primary Completion
- 2017-09-08
- Completion
- 2017-09-08
Countries
- United States
Study Locations
More Related Trials
-
PRecision Interventions for SMoking in the SCCS
NCT03521141 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Varenicline For Smokers In Recovery From Alcohol Dependence
NCT01092702 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
NCT04084210 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of a New Nicotine Replacement Therapy
NCT00764439 ·Status: COMPLETED ·Phase: PHASE2
-
Varenicline and Motivational Advice for Smokers With Substance Use Disorders
NCT00756275 ·Status: COMPLETED ·Phase: NA
-
Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
NCT00392379 ·Status: COMPLETED ·Phase: PHASE3
-
Non-Nicotine Agents for Smoking Cessation
NCT00108537 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace
NCT03272685 ·Status: COMPLETED ·Phase: PHASE3
-
Translational Neuropsychopharmacology Research of Nicotine Addiction
NCT02723162 ·Status: COMPLETED ·Phase: PHASE2
-
A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation
NCT01772641 ·Status: TERMINATED ·Phase: PHASE4
-
Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation
NCT01444131 ·Status: COMPLETED ·Phase: PHASE2
-
Financial Incentives for Homeless Smokers: A Community-based RCT
NCT04445662 ·Status: COMPLETED ·Phase: NA
-
Room Air Levels of Harmful and Potentially Harmful Constituents After Heated Tobacco Product Use and Cigarettes
NCT06476405 ·Status: COMPLETED
-
A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers
NCT01553084 ·Status: COMPLETED ·Phase: PHASE4
-
Nicotine Withdrawal Symptoms and Smoking Relapse
NCT01511614 ·Status: COMPLETED ·Phase: NA
-
Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation
NCT01406223 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes
NCT03559725 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment to Quit Smoking
NCT00018161 ·Status: COMPLETED ·Phase: PHASE2
-
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
NCT00790569 ·Status: COMPLETED ·Phase: NA
-
Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers
NCT01038245 ·Status: COMPLETED
-
Electronic Cigarettes and Reactivity to Smoking Cues
NCT01782599 ·Status: RECRUITING ·Phase: NA
-
The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse
NCT00773422 ·Status: COMPLETED ·Phase: PHASE2
-
Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3
NCT00390559 ·Status: COMPLETED ·Phase: NA
-
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism
NCT05947162 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes
NCT03612960 ·Status: COMPLETED ·Phase: NA